Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status

Journal of the National Cancer Institute

Volumn 88, Issue 22, 1996, Pages 1652-1658

  Diel, Ingo J ^a,b   Kaufmann, Manfred ^a   Costa, Serban D ^a   Holle, Rolf ^a   Von Minckwitz, Gunter ^a   Solomayer, Erich F ^a   Kaul, Sepp ^a   Bastert, Gunther ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BREAST CANCER; BREAST SURGERY; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; ILIUM; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0029804573     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.22.1652     Document Type: Article

References (41)

1. Rosen PR, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N0M0) breast carcinoma. J Clin Oncol 1989;7:355-66.
2. Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Perez JE, et al. Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am J Clin Oncol 1988;11:618-22.
3. Kinne DW. Primary treatment of breast cancer: surgery. In Harris JR, Hellman S, Henderson IC, Kinne DW, editors. Breast diseases. 2nd ed. Philadelphia: Lippincott, 1991:347-73.
4. Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink HM, et al. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer 1981;44:85-90.
5. Redding WH, Coombes RC, Monaghan P, Clink HM, Imrie SF, Deamaley DP, et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983;2:1271-4.
6. Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet JC, et al. Micrometastases in bone marrow in patients with primary breast cancer evaluation as an early predictor of bone metastases. Br Med J 1987;295:1093-6.
7. Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A 1987;84:8672-6.
8. Untch M, Harbeck N, Eiermann W. Micrometastases in bone marrow in patients with breast cancer [letter]. Br Med J 1988;296:290.
9. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-56.
10. Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res 1991;51:2706-9.
11. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534-9.
12. Diel IJ, Kaufmann M, Costa SD, Bastert G. Monoclonal antibodies to detect breast cancer cells. In: DeVita VT, Hellman S, Rosenberg SA, editors. Important advances in oncology 1994. Philadelphia: Lippincott, 1994:143-64.
13. Beahrs OE, Henson DE, Hotter RU, Myers MH. Manual for staging of cancer. 3rd ed. Philadelphia: Lippincott, 1988.
14. Bastert G, Eichler A, Kaul S. Monoclonal antibodies against breast cancer. In: Rygaard, Brunner, Spang-Thomsen, editors. Immune deficient animals in biomedical research. Basel: Karger, 1987:224-7.
15. Kaul S, Windecker S, Bastert G. Monoclonal antibodies reactive with tumor-associated epitopes of breast mucin glycoproteins. Proc Am Assoc Cancer Res 1989;30:349.
16. Windecker S, Khazaeli MB, Lobuglio AF, Shaw DR, Kaul S. Circulating levels of TAG 12 breast carcinoma-associated antigen. Proc Am Assoc Cancer Res 1990;31:262.
17. Zotter S, Hageman PC, Lossnitzer A, et al. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988;11:55-101.
18. Taylor-Papadimitriou J. Report on the first international workshop on carcinoma-associated mucins. Int J Cancer 1991;49:1-5.
19. Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994.
20. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
21. Mansi JL, Berger U, Wilson P, Shearer R, Coombes RC. Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques. J Urol 1988;139:545-8.
22. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-26.
23. Dantas ME, Brown JP, Thomas MR, Robinson WA, Glode LM. Detection of melanoma cells in bone marrow using monoclonal antibodies. A comparison of fluorescence activated cell sorting (FACS) and conventional immunofluorescence (IF). Cancer 1983;52:949-53.
24. Stahel RA, Mabry M, Skarin AT, Speak J, Bernai SD. Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. J Clin Oncol 1985;3:455-61.
25. Lindemann F, Schlimolc G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685-9.
26. Ellis G, Ferguson M, Yamanaka E, Livingston RB, Gown AM. Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients. Cancer 1989;63:2509-14.
27. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Deamaley D, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991;27:1552-5.
28. Osborne MP, Rosen PP. Detection and management of bone marrow micrometastases in breast cancer. Oncology 1994;8:25-31.
29. 99mTc and radioiodine. Cancer Res 1994;54:4162-8.
30. Mansi JL, Berger U, McDonnell T, Pople A, Rayter Z, Gazet JC, et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 1989;7:445-9.
31. Fisher ER. Prognostic and therapeutic significance of pathological features of breast cancer. Natl Cancer Inst Monogr 1986;1:29-34.
32. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-81.
33. Fentiman IS, Mansel RE. The axilla: not a no-go zone [see comment citations in Medline]. Lancet 1991;337:221-3.
34. Wazer DE, Erban JK, Robert NJ, Smith TJ, Marchant DJ, Schmid C, et al. Breast conservation in elderly woman for clinically negative lymph nodes without axillary dissection. Cancer 1994;74:878-83.
35. Menard S, Bufalino R, Rilke F, Cascinelli N, Veronesi U, Colnaghi MI. Prognosis based on primary breast carcinoma instead of pathological nodal status. Br J Cancer 1994;70:709-12.
36. Sacks NP, Barr LC, Allan SM, Baum M. The role of axillary dissection in operable breast cancer. In: Wise L, Johnson H, editors. Breast cancer: controversies in management. Armonk, NY: Futura Publishing, 1994:187-201.
37. Cody HS, Urban JA. The role of axillary dissection in managing patients with breast cancer: the case for complete axillary clearance. In: Wise L, Johnson H, editors. Breast cancer: controversies in management. Armonk, NY: Futura Publishing, 1994:169-76.
38. Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat 1985;5:17-21.
39. Fisher B, Fisher ER. Transmigration of lymph nodes by tumor cells. Science 1966;152:1397-8.
40. Fisher B, Fisher ER. Barrier function of lymph node to tumor cells and erythrocytes. I. Normal nodes. Cancer 1967;20:1907-13.
41. Cancer Research Campaign (King's/Cambridge) trial for early breast cancer. A detailed update at the tenth year. Cancer Research Campaign Working Party. Lancet 1980;2:55-60.